Kodiak Sciences is trading 7.25% down at $90.00 in pre-market, with no confirmed company-specific announcement explaining the October 29 move. - Recent company materials highlight earlier positive DAYBREAK trial results. - A previously reported $350 million at-the-market offering is a potential financing overhang, but reporting does not establish it as the cause of the decline. - Broader market signals are mixed, not a clear same-direction explanation.